Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged >=35 years: a randomized controlled trial | Zendy

Lan N. Vuong | Zendy; Huy Tuan Phung | Zendy; Tuong M. Ho | Zendy

Open Access

Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged >=35 years: a randomized controlled trial

Author(s) -

Lan N. Vuong,

Huy Tuan Phung,

Tuong M. Ho

Publication year - 2015

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/dev038

Subject(s) - luteinizing hormone , controlled ovarian hyperstimulation , ovarian hyperstimulation syndrome , hormone antagonist , gonadotropin releasing hormone antagonist , follicle stimulating hormone , medicine , in vitro fertilisation , gonadotropin releasing hormone , endocrinology , assisted reproductive technology , live birth , ovarian reserve , hormone , antagonist , biology , infertility , pregnancy , receptor , genetics

Does luteinizing hormone (LH) supplementation improve live birth rate after in vitro fertilization (IVF) in patients aged ≥35 years receiving a gonadotrophin-releasing hormone (GnRH) antagonist protocol?

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research